Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,118 across all filing types
Latest filing 2022-07-25 Regulatory Filings
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
NEXTSTELLIS oral contraceptive now available in Australia 2 pages 204.0KB
Regulatory Filings Classification · 95% confidence The document is a joint press release announcing the availability of a new oral contraceptive product, NEXTSTELLIS, in Australia. It contains promotional and product launch information, quotes from CEOs, and company background details. There is no financial data, regulatory filing references, voting results, or management changes. The content is typical of a press release announcing a product launch rather than a financial report, regulatory filing, or shareholder communication. Therefore, the most appropriate classification is a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2022-07-25 English
Mayne Pharma appoints new CFO 2 pages 146.6KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement about the appointment of a new Chief Financial Officer at Mayne Pharma. It contains no financial statements, no detailed financial data, no regulatory certifications, or report publication notices. It is a management change announcement, specifically about a senior executive appointment. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on this announcement, confirming it is not a full report or other filing type.
2022-07-21 English
Notification of buy-back - MYX 5 pages 24.9KB
Transaction in Own Shares Classification · 100% confidence The document is titled 'Notification of buy-back' and details a buy-back of shares by Mayne Pharma Group Limited. It specifies the type of buy-back as an 'Employee share scheme buy-back', provides details on the number of securities to be bought back, the consideration (extinguishment of employee share loans), and key dates. There is no financial report or earnings data presented, only an announcement of a share repurchase activity. The document length is 3317 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of 'Transaction in Own Shares' (POS), which covers company buy-back or sale of its own shares.
2022-06-30 English
Notification of cessation of securities - MYX 4 pages 24.3KB
Regulatory Filings Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of performance rights securities for Mayne Pharma Group Limited. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is an announcement about changes in the company's issued securities, specifically the cessation of certain securities due to lapse of conditions. It does not contain financial statements, management discussion, or detailed financial data. It is not a report but an announcement related to securities status changes. This fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement about securities cessation that does not fit into more specific categories like Share Issue/Capital Change (SHA) because it concerns cessation (lapse) rather than issuance or capital increase. The document length is 3736 characters, which is relatively short and consistent with an announcement rather than a full report.
2022-06-23 English
Change in substantial holding 6 pages 201.7KB
Regulatory Filings
2022-06-23 English
Wilsons investor conference presentation 16 pages 964.3KB
Investor Presentation Classification · 95% confidence The document is a detailed presentation given at the Wilsons Rapid Insights Conference by Mayne Pharma Group Limited. It includes extensive company overview information, market themes, product performance metrics, strategic priorities, pipeline launches, and operational updates. The content is structured as a presentation with slides and charts, focusing on financial and strategic information for investors. There is no indication that this is an annual or interim report, audit report, or earnings release. It is not a regulatory filing or announcement of voting results. The document is clearly a presentation aimed at investors and analysts, consistent with an Investor Presentation filing type.
2022-05-25 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.